MAPT and Alzheimer disease: However, we observed different AV-1451 binding patterns within the regions when comparing two phospho-tau antibodies (PHF-1 and CP13) with different profiles on immunoreactivity with tau positive structures in AD that describe early (CP13) and later (PHF-1) tau development.